Male accessory gland inflammation prevalence in type 2 diabetic patients with symptoms possibly reflecting autonomic neuropathy

Rosita A Condorelli, Enzo Vicari, Aldo E Calogero, Sandro La Vignera

Male accessory gland inflammation or infection (MAGI) is a potentially undiagnosed complication of type 2 diabetes (DM2); specifically, we reported in a recent study that the frequency of MAGI was 43% among DM2 patients. In previous studies, we demonstrated that diabetic autonomic neuropathy (DAN) is associated with a peculiar ultrasound characterization of the seminal vesicles (SVs) in DM2 patients. The aim of the present study was to evaluate the frequency of MAGI in two different categories of DM2 patients (i.e., patients with and without symptoms that possibly reflect DAN) and the respective ultrasound characterizations. Sixty DM2 patients with a mean (±s.e.m.) age of 42.0 ± 6.0 years (range: 34–47 years) were classified according to the presence or the absence of symptoms that could possibly reflect DAN (group A: DM2 with symptoms possibly reflecting DAN, n = 28 patients and group B: DM2 without symptoms possibly reflecting DAN, n = 32 patients). The patients in Group A exhibited a significantly higher frequency of MAGI compared with those in group B patients (P < 0.05); moreover, the Group A patients exhibited a significantly higher frequency of ultrasound signs suggestive of vesiculitis (P < 0.05). Finally, the concentrations of lymphocytes but not the concentrations of the leukocytes in the semen were significantly higher (P < 0.05) in group A compared with group B.

Asian Journal of Andrology (2014) 16, 761–766; doi: 10.4103/1008-682X.125911; published online: 25 April 2014

Keywords: diabetic neuropathy; male accessory gland inflammation or infection; male infertility

INTRODUCTION

Male accessory gland inflammation or infection (MAGI) has been identified as a diagnostic category with a negative impact on male reproductive function and fertility. They share the following common characteristics: they are common diseases, they primarily have a chronic course, they rarely cause obstruction of the seminal pathways and they can exhibit unpredictable intracanalicular spread to one or more sexual accessory glands of the reproductive tract on one or both sides.

We recently reported an increased frequency of MAGI among patients with type 2 diabetes (DM2) and assumed that MAGI may represent a possible undiagnosed complication of this condition.1 We also reported differential ultrasound characterizations of the seminal vesicles (SVs) in these patients,2 particularly among those with diabetic autonomic neuropathy (DAN).3

Conventionally, MAGIs are classified into uncomplicated (prostatitis) and complicated forms (prostatovesiculitis and prostatovesiculo-epididymitis).4 In our clinical experience, ultrasound characterization represents a valid tool for the evaluation of the real anatomical extent of the inflammatory process.5

According to World Health Organization (WHO; 1993),6 MAGI is diagnosed when abnormal sperm parameters are found and associated with at least one factor A plus one factor B, one factor A plus one factor C, one factor B plus one factor C or two factors C (Table 1).

Based on these criteria, the aim of the present study was to evaluate the frequencies of MAGI in infertile DM2 patients, to compare patients with and without symptoms that possibly reflect DAN and to evaluate the ultrasonic characteristics of these patients.

PATIENTS AND METHODS

A total of 60 consecutive infertile DM2 patients were recruited over the last 2 years (June 2011–2013) from the Andrological Center of the University of Catania (Italy) during medical counseling for couples’ infertility and divided into the following two groups: group A, 28 DM2 patients with symptoms possibly reflecting DAN and group B, 32 DM2 patients without any symptoms that could possibly reflect DAN. Table 2 shows the main clinical characteristics of the two examined groups.

The enrolled patients had a mean (± standard error of the mean (s.e.m.)) age of 42.0 (±6.0) years (range: 34–47 years), a mean (± s.e.m.) body mass index (BMI) of 27.5 (±2.0) kg m⁻² (range: 25–30 kg m⁻²), a mean (± s.e.m.) glycosylated hemoglobin level of 9.1 (±2.6%) (range 7.6%–10.6%) and a mean (± s.e.m.) duration of diabetes of 7.0 (±4.0) years (range: 2.0–12.0 years).

Diagnoses of diabetic neuropathy according to the guidelines of 19th Annual Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes (EURODIAB) and the 8th International Symposium on Diabetic Neuropathy in Toronto, Canada, 13–18 October 2009 had been made for all examined...
patients. According to these criteria, we arbitrarily selected only patients with symptoms that could possibly reflect complete autonomic neuropathy (two or more clinical cardiovascular and gastrointestinal and genitourinary and pseudomotor signs of DAN) (Table 3).

Each enrolled patient underwent a complete andrological diagnostic work-up that included the following: (i) a physical examination, (ii) a sperm analysis, (iii) a hormonal evaluation and (iv) an ultrasound evaluation.

Exclusion criteria
The exclusion criteria were as follows:
1. Ultrasound signs of proximal (epididymal) and/or distal (ampullo-prostato-vesicular) obstruction
2. Hormonal disorders (i.e. hypogonadism, hyperestrogenism, hyperprolactinemia and hypothyroidism). Specifically, endocrine factors can affect sexual function and cause long pauses during ejaculation in men with reduced sexual frequencies. Therefore, we arbitrarily chose to exclude these patients to minimize factors that promote stasis in the SV
3. Idiopathic orthostatic hypotension, Shy-Drager syndrome, Addison’s disease, hypopituitarism, pheochromocytoma, hypovolemia, medications with anticholinergic or sympatholytic effects, amyloid neuropathy and other peripheral autonomic neuropathies.

Moreover, the patients were excluded if they exhibited any of the following:
- Cigarette smoking, alcohol consumption, occupational chemical exposure, fever, drugs taken within the 3 months prior to enrollment in this study, azoosperma, testicular volume <15 ml (testicular volume is significantly correlated with testicular function; specifically, sperm parameters are subnormal in patients with total testicular volumes (right plus left testicular volumes) below 30 ml as measured by orchidometry,9 past or present cryptorchidism or varicocele.

Measurement of glycated hemoglobin
HbA1c was determined by high-pressure liquid chromatography. The equipment, calibration and controls were from the Bio-Rad company (USA) for the model Variant II. The reference ranges were 3.7%–6.2% and up to 48 nmol mol⁻¹.

Measurement of serum hormone concentrations
The hormone assays were performed by electrochemiluminescence with a Hitachi-Roche (Cobas 6000) from Roche Diagnostics (Indianapolis, USA). The references interval were as follows: luteinizing hormone, 1.6–9.0 mIU ml⁻¹; follicle-stimulating hormone, 2–12 mIU ml⁻¹; estradiol, 8–43 pg ml⁻¹; total testosterone, 2.8–8 ng ml⁻¹ and prolactin, 4–15 ng ml⁻¹. Blood samples were drawn from all examined patients between 08:00 and 10:00.

Sperm analysis
Semen samples were collected by masturbation into sterile containers following 2–7 days of sexual abstinence and were transported to the laboratory within 30 min of ejaculation. According to the 2010 WHO guidelines, each sample was evaluated for seminal volume, pH, sperm count, progressive motility, morphology and round cell concentration.

Fructose levels in the semen were measured using a spectrophotometric method and were assessed one hour after ejaculation using the Mann resorcinol and HCl methods.10

The characterizations of the leukocytes in the semen were made with the traditional methods and flow cytometry for the correct identification of neutrophils and lymphocytes.

Seminal leukocytes (neutrophils)
The protocol used was adapted from that of Endtz.11 The working solution used for the test was obtained by adding 1 µl of H₂O₂ to 20 µl of a 0.09% 3,3’-diaminobenzidine tetrahydrochloride stock solution (DAB, ISOPAC, Sigma, Milan, Italy) in 40% ethanol. In each assay, 20 µl of semen were incubated with 20 µl of working solution in an Eppendorf tube for 5 min at room temperature. Before setting up the slide, 40 µl of PBS was added. Peroxidase-positive cells were
marked by yellow-brown-red staining, while peroxidase-negative cells remained colorless. At least 100 round cells were counted using an optical microscope at x>400 magnification, and the percentages of the peroxidase-positive and negative cells were evaluated. The total leukocyte counts are expressed in 10⁶ ml⁻¹ of semen.

**Leukocytes flow cytometric analysis (lymphocytes)**

The analyses were conducted with an EPICS XL Flow Cytometer (Coulter Electronics, IL, Italy), equipped with an argon laser at 488 nm and the following three fluorescence detectors: green (FL-1 at 525 nm), orange (FL-2 to 575 nm) and red (FL-3 at 620 nm). For each sample, 100,000 events were measured at low flow velocities and analyzed using Sistem II™, version 3.0.

To obtain the absolute leukocyte counts, 100 µl of each liquefied semen sample was incubated with a mixture containing Syto-16 green fluorescent nucleic acid stain to identify the spermatozoa and exclude debris (the final concentration was 200 nmol l⁻¹, Molecular Probes, Eugene, Oregon, USA), 7-amino-actinomycin D (7-AAD Via-Probe, BD Pharmingen, San Diego, CA, USA) to assess viability, anti-CD45-APC (pan-leukocyte antigen) to recognize white blood cells and anti-CD16-PE for PMN recognition. The addition of 100 µl of Flow-Count™ Fluospheres (Beckmann-Coulter, Fullerton, CA, USA) at 1034 beads per ml allowed for the determination of the absolute leukocyte count by flow cytometry. After incubation in the dark for 20 min at room temperature, 1 ml of PBS was added and the sample was analyzed by flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA, USA). For each test, 100,000 events were acquired.

**Ultrasound evaluation**

All patients underwent scrotal and transrectal ultrasound evaluation after one day of sexual abstinence before and one hour after ejaculation, using a transrectal 7.5 MHz biplan biconvex transducer (Esaote GPX Megas, Genova, Italy). We arbitrarily chose to examine patients after a single day of sexual abstinence to minimize factors that promote stasis in the SV.

The scrotal ultrasound evaluation was performed in two phases. In the first phase, the patient was in a supine position (with the penis resting on the suprapubic region), and in the second phase, the patient was in an upright position to allow for evaluations of reflux along the pampiniform plexus, testicular pain, testicular malposition and the extent of any fluid collections. The examination was performed with a GX Megas Esaote (Esaote SpA - Genova (Italy)) device, which was equipped with linear, high-resolution and high-frequency (7.5–14 MHz) transducers equipped with a GX Megas Esaote (Esaote SpA - Genova (Italy)) device, which was equipped with linear, high-resolution and high-frequency (7.5–14 MHz) transducers.

In the transrectal ultrasound evaluations of the prostates and the SVs, the following prostate ultrasound parameters were recorded: volume, parenchymal echogenicity and vascularization, the presence of parenchymal and/or ductal cysts, and/or calculi, and/or calcifications and/or area(s) of acinar ectasia. Moreover, the symmetry of the lobes and the characteristics of the venous periprostatic plexus were recorded.

The following direct SV ultrasound parameters were recorded: (i) body anteroposterior diameter (DAP); (ii) fundus DAP; (iii) parietal thickness of the right and left SVs and (iv) the numbers of polycyclic areas within both SVs. These values were used to calculate the following derived parameters: (i) fundus/body ratio; (ii) differences of the parietal thicknesses between the right and the left SVs; (iii) differences in interparietal diameter between the right and the left SVs and (iv) pre- and postejaculatory DAP differences (Figure 1).

The operator (Single Laboratory Validation) repeated the measurements of these parameters twice and these parameters are expressed as the mean in the final report. For measurements below 1 mm, the calculations were performed on ultrasound paper with a millimetric measurement system.

Table 4 shows the ultrasound criteria (published by our group) that were adopted by our clinical practice for the confirmation of clinical diagnoses of MAGI.⁶

The protocol was approved by the Institutional Review Board and an informed written consent was obtained from each patient and all controls.

**Statistical analyses**

The results are reported as the means ± s.e.m. throughout the study. The data were analyzed with one-way analysis of variance followed by Duncan’s multiple range tests and Student’s t-tests for direct comparison of the two groups. Statistical analyses were performed using Statistical Package for Social Sciences 9.0 for Windows. P < 0.05 was accepted as statistically significant.

**RESULTS**

No patients exhibited alterations in the examined hormonal parameters (Table 5). In group A, the mean values of the following sperm parameters were significantly lower than those of group B: density, progressive motility, normal forms, ejaculate volume, concentration of

![Figure 1: Ultrasound parameters of the seminal vesicles (SVs) examined in the present study. (a) Body anteroposterior diameter (DAP), fundus DAP and fundus/body ratio; (b) Parietal thicknesses of the right and left SVs, difference in the parietal thicknesses between the right and the left SV and difference between the interparietal diameters of the right and the left SVs; (c) Number of polycyclic areas within both SVs; (d) Pre- and postejaculatory DAP differences.](image-url)
lymphocytes and fructose levels \((P < 0.05, \text{Table 5})\). Specifically, isolated oligospermia was observed in 43% of the Group A patients and in 23% of the Group B patients. Isolated teratozoospermia was observed in 18% of group A patients and in 10% of group B patients. Isolated asthenozoospermia was observed in 17% of group A and 10% of group B patients. Oligoteratozoospermia was detected in 36% of group A and in 20% of group B patients. Oligoaethnozoospermia was detected in 28% of group A and 18% of group B patients. Oligoaethnozoospermia was detected in 46% of group A and 32% of group B patients. The condition of leucocytospermia was detected in 45% of the patients in group A and in 39% of the patients in group B (this difference was not significant). The group A patients exhibited a significant increase in the concentration of seminal lymphocytes compared with the group B patients \((2.3 \pm 1.5 \text{ vs } 0.5 \pm 0.3 \text{ million per ml); } P < 0.05\).

All of the diagnostic criteria that are used in clinical practice for the diagnosis of MAGI were found to be higher in Group A, with the exceptions of the presence in the anamnesis of reported sexually transmitted infections and the criteria of the C factor for the frequency of leucocytospermia and positive semen cultures (Table 6). Finally, total of 18 patients in group A and 14 patients in group B exhibited diagnoses of MAGI.

The ultrasound evaluations of the patients with DM2 and associated MAGI comparing patients with \((n = 18)\) and without \((n = 14)\) symptoms possibly reflecting DAN revealed significantly increased frequencies of all ultrasound criteria suggestive of vesiculitis in the patients with symptoms possibly reflecting DAN \((P < 0.05)\) (Table 7). A total of nine patients with symptoms possibly reflecting DAN (50%) and three (21%) patients without symptoms possibly reflecting DAN exhibited ultrasound findings of prosta-vesiculo-epididymitis (i.e. more extensive anatomical involvement). Finally, the DM2 patients with MAGI and symptoms possibly reflecting DAN were significantly different from the DM2 patients with MAGI without symptoms possibly reflecting DAN symptoms in the following semen parameters: sperm density, concentration of lymphocytes, ejaculate volume and fructose levels (Table 8).

### DISCUSSION

In a recent study, we showed that the prevalence of MAGI in DM2 patients is approximately 43%.\(^1\) The present study confirms the previous data and supports this hypothesis through the evaluations of two different groups of patients with DM2 (i.e. those with and without symptoms possibly reflecting DAN). Specifically, the patients with symptoms of DAN exhibited higher frequencies of MAGI compared with the DM2 patients without symptoms of DAN, and the ultrasound characterizations of the patients with DM2 and MAGI showed that the frequencies of meeting the criteria suggestive of vesiculitis were significantly higher in the group with symptoms possibly reflecting DAN compared with the group without symptoms possibly reflecting DAN. Furthermore, the frequencies of ultrasound findings of prosta-vesiculo-epididymitis (i.e. more extensive anatomical involvement) were higher in the group with symptoms possibly reflecting DAN than in the group without symptoms possibly reflecting DAN. Moreover, the semen qualities of the DM2 patients with symptoms possibly reflecting DAN were lower than those of the DM2 patients without symptoms of DAN; specifically, the concentrations of leukocytes in the ejaculates did not aid differential diagnoses, but the concentrations of seminal lymphocytes were significantly higher in the patients with symptoms possibly reflecting DAN. Finally, the sperm densities, semen lymphocytes concentrations, ejaculate volumes and fructose levels were significantly different between the DM2 patients with MAGI that had or did not have symptoms possibly reflecting DAN.

In our opinion, the most relevant aspects of the present study are as follows:

1. Greater inflammatory involvement of the SVs in patients with symptoms possibly reflecting DAN was demonstrated by the higher frequency of abnormal ultrasound findings and the reduced concentrations of fructose in the semen of these patients.

2. Differential diagnoses were improved by the characterization of the lymphocytes in the semen compared with only characterizing the leucocytes, which is the normally recommended clinical practice\(^9\) (WHO, 2010).

We demonstrated that DAN may cause alterations in the structures and functions of the SVs. Specifically, the innervations of the SVs arise from the pelvic nerve and the hypogastric plexus, which supplies adrenergic and cholinergic fibers.\(^14\) The cholinergic fibers are found in

---

**Table 4: Ultrasound criteria for MAGI**

Prostatitis is suspected in the presence of \(>2\) of the following ultrasonographic signs:

1. Asymmetry of the gland volume;
2. Areas of low echogenicity;
3. Areas of high echogenicity;
4. Dilatation of periprostatic venous plexus;
5. Single or multiple internal similar cystis areas;
6. Area(s) of moderate increased of vascularity (focal or multiple).

**Vesiculitis is suspected in the presence of \(>2\) of the following ultrasonographic signs:**

1. Increase (>14 mm) anteroposterior diameter mono- or bilateral;
2. Asymmetry>2.5 mm (normal 7–14 mm) compared with the contralateral vesicle;
3. Reduced (<7 mm) anteroposterior diameter mono- or bilateral;
4. Glandular epithelium thickened and/or calcified;
5. Polycyclic areas separated by hyperechoic septa in one or both vesicles;
6. Fundus/body ratio>2.5;
7. Fundus/body ratio<1;
8. Anteroposterior diameter unchanged after recent immediate ejaculation.

**Epididymitis is suspected in the presence of \(>2\) of the following ultrasonographic signs:**

1. Increase in size of the head (cranio-caudal diameter>12 mm) and/or of the tail (cranio-caudal diameter>6 mm) (finding single or bilateral);
2. Presence of multiple microcystis in the head and/or tail (finding single or bilateral);
3. Low echogenicity or high echogenicity mono- or bilateral;
4. Large hydrocele mono- or bilateral;
5. Enlargement in superior part of the cephalic tract and superior/inferior part ratio>1;
6. Unchanged anteroposterior diameter of tail after ejaculation.

**Table 5: Hormonal and sperm parameters of the two examined groups**

| Parameter                  | Group A (DAN+) | Group B (DAN−) | \(P\) |
|----------------------------|----------------|----------------|------|
| **Hormonal parameters**    |                |                |      |
| FSH (mIU ml\(^{-1}\))     | 3.3±2.4        | 3.0±2.0        | 0.889|
| LH (mIU ml\(^{-1}\))      | 4.8±1.6        | 4.2±2.2        | 0.955|
| Testosterone (ng ml\(^{-1}\)) | 5.1±2.2      | 5.3±1.1        | 0.888|
| Estradiol (pg ml\(^{-1}\)) | 11.0±6.0      | 15.0±5.0       | 0.877|
| Prolactin                 | 5.0±5.0        | 6.0±3.0        | 0.899|
| **Sperm parameters**      |                |                |      |
| Density (million per ml)  | 18.0±12.0*     | 45.0±12.0*     | <0.05|
| Motility (%)              | 24.0±12.0*     | 33.0±7.0*      | <0.05|
| Normal forms (%)          | 3.0±3.0*       | 8.0±2.0        | <0.05|
| Ejaculate volume (ml)     | 1.2±0.9*       | 2.1±1.2        | <0.05|
| Leukocytes (million per ml) | 1.5±0.6*     | 1.2±0.4        | 0.877|
| Lymphocytes (million per ml) | 2.3±1.5*   | 0.5±0.3        | <0.05|
| Fructose (mg%)            | 155.0±66.0*    | 267.0±88.0*    | <0.05|

DAN+- and DAN−; with or without diabetic autonomic neuropathy; FSH: follicle-stimulating hormone; LH: luteinizing hormone.
Table 6: Detection of the diagnostic criteria for MAGI in the two groups examined

| Criteria                                      | Frequency (%) | Group A | Group B | P    |
|-----------------------------------------------|---------------|---------|---------|------|
| Factor A: history and physical signs          |               |         |         |      |
| Urinary infection (a)                         | 40            | 25      |         | <0.05|
| Epididymitis (a)                              | 55            | 30      |         | <0.05|
| Sexually transmitted disease (a)              | 20            | 18      |         | 0.778|
| Thicken epididymis (s)                        | 53            | 36      |         | <0.05|
| Tender epididymis (s)                         | 56            | 33      |         | <0.05|
| Tender vas deferens (s)                       | 50            | 32      |         | <0.05|
| Abnormal EPS                                  | 60            | 40      |         | <0.05|
| Abnormal UAPM                                 | 62            | 40      |         | <0.05|
| Factor B: ejaculate signs                     |               |         |         |      |
| Leukocytes>1 million per ml                   | 45            | 39      |         | 0.882|
| Positive semen culture                        | 38            | 34      |         | 0.876|
| Abnormal appearance                           | 65            | 50      |         | <0.05|
| Increased viscosity                           | 68            | 45      |         | <0.05|
| Increased pH                                  | 49            | 30      |         | <0.05|
| Abnormal biochemistry of SP                   | 55            | 35      |         | <0.05|
| Overall frequency of MAGI                    | 64            | 44      |         | <0.05|

Table 7: Ultrasound evaluations of the DM2 patients with MAGI (DAN+ vs DAN−)

| Criteria                                      | Frequency (%) | Group A | Group B | P    |
|-----------------------------------------------|---------------|---------|---------|------|
| Prostatitis                                   |               |         |         |      |
| Asymmetry of the gland volume                 | 18            | 16      |         | 0.766|
| Areas of low echogenicity                     | 22            | 24      |         | 0.876|
| Areas of high echogenicity                    | 20            | 22      |         | 0.914|
| Dilatation of PPVP                            | 23            | 21      |         | 0.897|
| Single or multiple internal LCA               | 23            | 22      |         | 0.889|
| increased of vascularization                  | 20            | 18      |         | 0.876|
| Epididymitis                                  |               |         |         |      |
| Increase of CCD (head or tail)                | 18            | 15      |         | 0.766|
| Multiple microcystis                           | 20            | 22      |         | 0.813|
| Echogenicity (low or high)                    | 22            | 20      |         | 0.886|
| Hydrocele                                     | 18            | 16      |         | 0.834|
| Superior/inferior part>1 (head)               | 21            | 23      |         | 0.842|
| Unchanged DAP a.e. (tail)                     | 20            | 19      |         | 0.987|
| Vesiculitis                                   |               |         |         |      |
| Increase DAP (mono- or bilateral)             | 27            | 10      |         | <0.05|
| Asymmetry>2.5 mm                              | 25            | 10      |         | <0.05|
| Reduced DAP (mono or bilateral)               | 22            | 12      |         | <0.05|
| Thickened and/or calcified wall               | 20            | 12      |         | <0.05|
| Polycystic areas                              | 28            | 16      |         | <0.05|
| Fundus/body ratio>2.5                         | 55            | 35      |         | <0.05|
| Fundus/body ratio<1.5                         | 23            | 12      |         | <0.05|
| DAP unchanged after ejaculation               | 60            | 30      |         | <0.05|

a.e.: after ejaculation; CCD: cranio-caudal diameter; DAN+ and DAN−: with or without diabetic autonomic neuropathy; DAP: anteroposterior diameter; DM2: type 2 diabetes; LCA: like cystic areas; PPVP: periprostatic venous plexus.
the epididymis has been confirmed by studies performed using the vasectomy model,36,37 and these models produce evidence of local inflammatory responses following the procedure. However, in patients with leukocytospermia, seminal citric acid concentrations (a marker of prostate function) appear to be lower, which suggests that prostatitis is the main cause of the presence of leukocytes in the semen. However, there is no clear evidence regarding the potential role of altered contractile and/or secretory functions of the VS in terms of the presence of leukocytes and/or lymphocytes in the semen.

In conclusion, this study confirmed the elevated frequency of MAGI in DM2 patients with symptoms that possibly reflect autonomic neuropathy and suggests that DAN is a probable risk factor for the development of MAGI. An important role may be attributed to the greater frequencies of ultrasonic signs of vesiculitis, and further studies should clarify the role of seminal vesicles in these patients and should specifically clarify the origin of seminal lymphocytes.

AUTHOR CONTRIBUTIONS
SLV and RAC are the principal investigators. AEC and EV have performed the statistical analysis and the final revision of the manuscript.

COMPETING INTERESTS
The authors declare that they have no competing interests.